Dr.Oracle answers clinical questions with citations from guidelines, published research and FDA drug labels, built for students, residents and physicians rather than patients.
Used this tool? Rate it
Used this tool? Rate it
Dr.Oracle is a medical question-answering platform aimed at clinicians and medical trainees, built to return guideline-directed answers with citations rather than unsourced prose. You ask a clinical question in plain language and receive an explanation drawn from published guidelines and research, with references attached so the reasoning can be traced back to primary sources. The homepage positions it as The World's Most Powerful Medical A.I., promising instant, precise and in-depth explanations directly from up-to-date guidelines and clinical research.
The legal self-description is narrower and more precise than the marketing one, and the difference matters. The terms of service state that TheDeep, LLC operates DrOracle.ai, a text generation service intended to assist with general medical and scientific inquiry. That phrasing — a text generation service for general inquiry — sets the product's actual boundary: it is a reference and study aid, not a diagnostic device, not a clinical decision support system in the regulatory sense, and not a substitute for professional judgment.
Coverage spans 24 specialties, from cardiology and infectious disease through oncology, emergency medicine, obstetrics and gynecology, radiology, anesthesiology, and pathology. The intended audience is medical students, residents, physicians, physician associates, and nurse practitioners — not patients. That distinction is stated explicitly by the company and is repeated throughout this page because it governs how the tool should be used.
Despite the name, Dr.Oracle has no connection whatsoever to Oracle Corporation. The product is operated by TheDeep, LLC, a company registered in Delaware, and the name is a medical metaphor rather than a corporate reference. This is worth stating plainly because searching for medical AI alongside the word Oracle surfaces extensive coverage of Oracle Health — the healthcare EHR business Oracle Corporation acquired through Cerner — which is an entirely different product from an entirely different company. Nothing on Dr.Oracle's site claims any partnership, licensing, or affiliation with Oracle Corporation, and none exists.
Company identity is unusually consistent across channels here. The terms name TheDeep, LLC. Apple's developer registry lists the seller as TheDeep, LLC. for the iOS app under the bundle identifier ai.thedeep.droracleios. Google Play's developer disclosure gives a matching entity with a physical address: THEDEEP LLC, 651 N Broad St, Middletown, DE 19709, United States, along with a support email and phone number. Three independent registries agreeing on the operator is a stronger identity signal than most tools in this category provide.
The central feature is question answering with attached references. The company's stated aim is to deliver immediate, accurate, and evidence-based answers to your most complex medical questions, supported by the latest peer-reviewed literature. The vendor describes the sourcing base as official medical guidelines, published research, FDA drug labels, and real case reports, continuously updated, and reviewed by a multidisciplinary physician-led advisory board.
The citation layer is the feature that distinguishes this class of tool from a general chatbot. Whether a given citation actually supports the claim it is attached to remains something the user must check — the terms explicitly require that verification, as covered below.
Entering patient findings returns a structured list of diagnostic possibilities. The company frames the purpose as cognitive rather than decisional: input patient findings and get a comprehensive differential diagnosis, helping you consider all possibilities and avoid cognitive biases. Read that carefully — the stated value is broadening the clinician's consideration set, not narrowing it to an answer. Used that way it is a checklist against premature closure; used as a diagnosis generator it would exceed what the product's own terms support.
Research Mode performs comparative appraisal across multiple papers at once. The company describes it as a way to rapidly evaluate the strengths and weaknesses of up to 25 papers at a time to rapidly accelerate the research process. For literature reviews, journal club preparation, or scoping a research question, batch appraisal is genuinely useful — though appraisal quality still requires the reader's own methodological judgment.
An unusual design choice, and one worth taking seriously: the company maintains its own internal clinical guideline articles, which are written and updated by a multidisciplinary team of editors, and states plainly that it does not use AI to generate its core knowledge base. Combined with the claim that generated answers are reviewed regularly by a Medical Advisory Board, this describes a human-in-the-loop architecture rather than a pure retrieval-and-generate pipeline. These are vendor statements and cannot be independently audited from outside, but they are specific and falsifiable claims rather than vague assurances.
The company states that it does not accept any funding from pharmaceutical companies, presenting this as a guarantee of unbiased information. For a tool that surfaces drug and treatment recommendations, funding independence is a material disclosure, and stating it explicitly is better practice than staying silent. As with the editorial claims, this is self-reported.
Content spans 24 named specialties: cardiology, dermatology, endocrinology, gastroenterology, hematology, infectious disease, nephrology, neurology, oncology, ophthalmology, orthopedics, otolaryngology, psychiatry, pulmonology, rheumatology, urology, emergency medicine, family medicine, internal medicine, pediatrics, obstetrics and gynecology, radiology, anesthesiology, and pathology.
The most common use is quick lookup during clinical work — checking a guideline-directed management step, confirming a dosing consideration, or refreshing on an uncommon presentation between patients. The company frames this as learning on the job, between patients. Given the platform's own prohibition on entering identifiable patient information, questions must be phrased generically rather than as case consultations.
Students and residents use it to prepare presentations before rounds. The company markets this directly, arguing that clerkship grades and letters of recommendation often come down to the quality of clinical presentations. Preparing a differential and management rationale in advance is a defensible study workflow.
USMLE preparation is an explicitly marketed use, positioned as a complement to question banks — studying alongside a Q-bank to build deeper understanding of the underlying material rather than replacing practice questions.
Research Mode's batch appraisal suits scoping reviews, journal club preparation, and early-stage research where the task is triaging which papers merit close reading.
Because the sourcing base includes FDA drug labels, medication questions are a natural fit. Note the caveat from user feedback discussed below regarding commercial drug names.
Educators use the generated explanations as starting material for teaching points, with the citation trail allowing verification before content reaches learners.
The product is designed for healthcare professionals and is explicitly not intended for direct patient use. Patients seeking answers about their own health should consult a clinician instead — this tool is not built for that purpose and its own documentation says so.
Registration is required, and the service is paid-only with a free trial for new users. The company states it offers a free 7-day trial for all new users.
This step is a compliance requirement, not a style preference. The terms instruct users not to include sensitive personal health identifiers — name, date of birth, medical record numbers, address, or anything else identifying — and require that questions be phrased as general medical or scientific inquiries rather than personal medical consultations. Convert a real case into a de-identified clinical pattern before asking.
Within those constraints, specificity improves answers. Age range, relevant comorbidities, salient findings, and the decision you are facing produce more useful output than a bare topic keyword.
Use standard question answering for point-of-care lookup and Research Mode when the task is appraising a body of literature rather than answering a single question.
This is the non-negotiable step. The terms state that you should independently verify any references or claims made by the AI before taking any consequential action, and that reliance on information provided by the service is solely at your own risk. Open the cited source, confirm it says what the answer claims, and check its date.
The company's own guidance is that healthcare professionals should exercise their own clinical judgment and consider current clinical guidelines when making patient care decisions. The tool informs the decision; it does not make it.
User feedback has specifically flagged old sources appearing in answers to current clinical questions. Guideline currency is the entire value proposition of this category, so date-checking is the highest-yield verification habit.
Reported difficulty with commercial drug names makes generic nomenclature the safer input. This is also better practice for internationally portable answers, since brand names vary by market.
For any decision with real consequences, confirm against the actual society guideline rather than stopping at the summary. The tool is a faster route to the guideline, not a replacement for reading it.
The stated design intent is bias reduction through broader consideration. Using the output to confirm you have not missed something preserves that benefit; using it to select a diagnosis inverts it.
Build the habit of converting cases to generic patterns. The platform is not HIPAA-compliant and has no BAA in place, so entering protected health information is both a terms violation and a genuine privacy exposure.
Given a user report of being charged without receiving a requested payment reminder, do not rely on the platform's own notification to prompt you. Note the company states it honors all refunds within 30 days.
The seven-day window is enough to test the tool against the specific question types you actually encounter. User experiences differ substantially, so your own trial is more informative than any aggregate rating.
The strongest fit. Exam preparation, pre-rounding, and rapid concept explanation align with both the marketing and the product's educational self-definition. The 4.74 App Store rating across more than a thousand reviews suggests this audience is broadly satisfied.
A reasonable fit for reference lookup and staying current, provided the verification discipline is maintained. Physicians already carry the professional obligation to validate sources, which is exactly what the terms require.
Explicitly named in the target audience and served by the same guideline-lookup and differential-support workflows.
Research Mode and the citation trail support literature triage and teaching material preparation.
Patients and caregivers seeking guidance about their own care should not use this tool — it is not intended for direct patient use, and the company says so. Anyone needing to process protected health information must not use it, as it is not HIPAA-compliant and no BAA is available. Institutions requiring regulatory clearance for clinical decision support should note that nothing in the public documentation claims device clearance of any kind. Non-English-speaking users should note the iOS app registers English as its only interface language.
Dr.Oracle runs on the web and on native mobile apps, with the company stating availability on iPhone/iPad, Apple Vision, Android, and Web Browser, and that one account works on all devices.
The iOS app launched on 2024-01-02 and reached version 3.0.0 on 2026-05-12, requiring iOS 15.1 or later. It is listed under Education with Medical as a secondary category and is free to download, with access sold through in-app subscription. Its registered interface language is English only. Apple rates it 17+ and attaches the content advisory Frequent/Intense Medical/Treatment Information — a platform-assigned classification that reflects the clinical nature of the content.
The Android app is published under the identifier ai.thedeep.droracleandroid by the same developer entity. One inconsistency is worth noting for anyone assessing suitability by store metadata: Google Play rates the app Everyone while Apple rates it 17+, so the two stores classify identical content differently.
There is no publicly documented API, and the platform's terms prohibit using the service as input into other services, websites, or databases, which forecloses programmatic integration regardless.
Dr.Oracle is a paid subscription product. The company is direct about this, stating that Dr.Oracle AI is a paid-only service with free trials available to new users. The apps are free to download; access is sold by subscription.
Verified pricing detail is limited because the site publishes no anonymous-accessible pricing page. Two figures come from user reports on Google Play rather than from the company: one reviewer describes the cost as roughly $21.67 per month and considers it steep, while another reports a charge of $24.99. These are user-reported amounts, not official published rates, and should be treated as indicative of the general price band rather than as a current price list. Anyone evaluating the product should confirm current pricing inside the app before subscribing.
Two company-stated terms are relevant to the purchase decision:
The 30-day refund statement is more generous than the industry norm for subscription software and is a meaningful consumer protection if applied as written. It sits alongside one user report of being charged without a requested reminder — which is why setting an independent reminder is advisable regardless of stated policy.
The most direct comparison is OpenEvidence, which the company treats as its principal competitor — it maintains a blog page specifically about OpenEvidence alternatives, and its own benchmark claims name OpenEvidence first. Notably, user opinion runs in both directions on this comparison: the vendor claims to outperform it, while one Google Play reviewer reports moving to Dr.Oracle after OpenEvidence restricted free access for non-US doctors and finding the experience substantially worse. Neither position is independently verified.
UpToDate remains the established reference standard in this space and is the incumbent most clinicians already know. One App Store reviewer explicitly frames Dr.Oracle as more efficient and concise for targeted questions, while UpToDate's depth means more reading to reach a specific answer. The trade-off is between editorial pedigree and retrieval speed.
General-purpose assistants such as ChatGPT, Claude, and Gemini can answer medical questions but lack curated guideline corpora and citation guarantees. The vendor's differentiation argument is that its AI has access to curated guidelines and literature that ChatGPT does not, and that it evaluates the strength of the research it cites. MediSearch is another specialized option named in the company's own comparison set.
For a clinical tool, this section carries more weight than the feature list. Read it fully before adopting the product into any workflow that touches patient care.
This is the single most important constraint, and the company states it clearly. Its disclaimer specifies that content is intended for educational and informational purposes only, should not be considered as medical advice, diagnosis, or treatment recommendations, and that users should always seek the advice of a physician or other qualified healthcare provider regarding a medical condition. It further states the service is designed for use by healthcare professionals, is not intended for direct patient use or as a substitute for professional medical judgment, and that clinicians should exercise their own clinical judgment and consider current clinical guidelines when making patient care decisions.
Nothing on this page should be read as suggesting the tool can replace clinical training, examination, or consultation.
A critical operational constraint that the marketing surface does not foreground: the terms state that DrOracle.ai is not a HIPAA-compliant platform, that no Business Associate Agreement is in place, and that the service should not be used to process Protected Health Information as defined under HIPAA. Users are instructed not to include sensitive personal health identifiers and to phrase questions as general medical or scientific inquiries rather than personal medical consultations.
This sits in tension with the vendor's marketing description of the product as a point-of-care clinical support tool adopted by hospital systems. Both statements can be true simultaneously — one can consult a general reference at the point of care without entering identifiable data — but clinicians and institutions must understand that the platform is contractually a general-inquiry reference tool, not a system cleared to touch patient records.
The headline benchmark deserves careful reading. The site advertises Highest Scores on the United States Medical Licensing Exams in History, reporting STEP 1 100%, STEP 2 100%, and STEP 3 97.5%, and claims to outperform OpenEvidence, ChatGPT 5, Claude 4, Google Gemini, and MediSearch. The supporting note states that results were produced from official sample USMLE exams, as detailed by Kung et al., 2023, with a link to a self-published 2024 results spreadsheet.
The Kung et al. citation requires precise interpretation, because it is easy to misread as third-party validation of this product. Verified through the National Library of Medicine's own records, that paper is titled Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models, published in PLOS Digital Health in February 2023. The system it evaluated was ChatGPT, not Dr.Oracle, and its authors are unaffiliated with TheDeep, LLC. The company is citing it for methodology — the use of official sample exams as a benchmark — not as evidence about its own system. That is a legitimate citation practice, but it does not constitute independent verification of Dr.Oracle's accuracy.
The company's own scores come from its self-published spreadsheet: not peer-reviewed, not independently replicated, and not audited. Sample-exam performance also measures multiple-choice recall under test conditions, which is a weak proxy for accuracy on open-ended clinical questions in practice.
The site's FAQ answers the question of whether the product hallucinates with a flat denial, stating it has never had a report of hallucinations. This claim should be treated with skepticism for two reasons. First, absence of reports is not absence of occurrence, and no retrieval-augmented language system available today can guarantee freedom from fabrication. Second, and more tellingly, the company's own terms of service say something quite different: TheDeep, LLC does not guarantee the accuracy, integrity, or quality of any content generated by or submitted through the Service, and users must independently evaluate all content before acting on it and may not rely solely on any content created by the Service.
When the marketing page and the contract disagree, the contract is the operative statement. Treat outputs as requiring verification.
There is no bylined coverage of Dr.Oracle in major technology or healthcare trade publications. The press items that surface are syndicated republications of the company's own announcement across financial newswires, which are vendor statements rather than journalism. The self-reported figure of more than 53,000 medical professionals has no independent confirmation.
App store ratings are the substantive third-party evidence, and they diverge by platform. The App Store rating is 4.74 across 1,054 reviews — a large enough sample to carry real weight and a genuinely strong score. Google Play sits at 4.0 across 369 reviews. Both are positive; the gap suggests platform-specific experience differences rather than a contradiction.
A minor but telling detail on self-reported figures: the homepage badge still advertises 300+ Reviews in App Store, while the store itself now shows 1,054. The direction of that error is harmless — the product is doing better than its own site claims — but it indicates the marketing surface is not kept in sync with verifiable external data, which is worth remembering when weighing the site's other unaudited numbers.
Balanced against the strong aggregate scores, individual reviews raise substantive concerns. One reviewer identifying as a non-US physician reports that it takes forever to respond, does not know commercial names of drugs, and cited sources from 1986 for a simple clinical question, adding that prompting for the latest guidelines yielded little success. That report contradicts the currency claim at the heart of the product's value proposition. It is one review among hundreds and should be weighted accordingly, but it is specific and checkable in a way that generic praise is not — and it is precisely the failure mode a clinician should test for during the trial.
An Android usability complaint also appears: the keyboard must be minimized before questions will send.
Access is granted for personal, non-commercial use only. Republishing generated content requires clearly citing the service and its context, and misrepresenting the source or nature of content is prohibited. Systematic or automated data collection — scraping, mining, extraction — is barred, as is using the service as input into other services, websites, or databases.
Use requires being at least 18 years old, and the company states it will terminate accounts and remove information promptly if it becomes aware of an underage user.
Several further provisions shape what happens to what you type and what the company promises about reliability.
On warranties, the terms state the company does not warrant that the services will be uninterrupted or error free, will be secure or available at any particular time or location, that defects will be corrected, or that results will meet your requirements.
On what happens to your questions, the terms describe an unusual privacy architecture. Questions you submit are associated with your account through an anonymous internal identifier, and the company states that DrOracle.ai staff cannot look up any individual user's question history. Users may unlink questions at any time, after which they cannot be retrieved by either the user or staff. Alongside that, submitting content does grant TheDeep, LLC a worldwide license to use, store, reproduce, and modify that content for the limited purposes of operating and improving the service, including internal quality assurance review of AI responses. The company also reserves the right to transform particularly helpful questions and answers into generalized educational material for the public, stating that wording and specifics are rephrased so the result is not identical to any user's original submission.
On patient data specifically, the site's disclaimer states: We do not collect, store, or process any personal health information (PHI) or personally identifiable information (PII) of patients — a commitment that only holds if users follow the instruction not to enter identifying details in the first place.
On mobile data handling, Google Play's data safety disclosure indicates the app may share Device or other IDs with third parties, may collect personal info and app activity, encrypts data in transit, and supports deletion requests.
Finally, on content freshness, the company acknowledges that medical knowledge and guidelines evolve rapidly and directs users to verify critical information against the latest clinical guidelines and primary literature.
No. There is no relationship of any kind. Dr.Oracle is operated by TheDeep, LLC, registered in Delaware, and the name is a medical metaphor. Searches combining medical AI with Oracle often surface Oracle Health, the EHR business Oracle Corporation acquired via Cerner, which is a completely separate product from a completely separate company.
No, and it is not designed to. The company states its content is for educational and informational purposes only, is not medical advice, diagnosis, or treatment recommendations, and that you should always seek the advice of a physician or other qualified healthcare provider. The product is built for healthcare professionals and is explicitly not intended for direct patient use. If you have a health concern, consult a clinician.
Not independently. The reported scores of 100%, 100%, and 97.5% across the three USMLE steps come from the company's own self-published 2024 results, which are neither peer-reviewed nor independently audited. The referenced Kung et al. 2023 paper studied ChatGPT — not Dr.Oracle — and is cited for its benchmark methodology using official sample exams, not as validation of this product. Treat the scores as vendor claims.
No. The terms state the platform is not HIPAA-compliant, has no Business Associate Agreement in place, and should not be used to process Protected Health Information. You are instructed not to include names, dates of birth, medical record numbers, addresses, or any other identifying details, and to phrase questions as general medical or scientific inquiries rather than personal consultations. De-identify every case before asking.
The company's FAQ claims it has never had a report of hallucinations. That claim warrants skepticism: no current AI system can guarantee freedom from fabrication, and the company's own terms state it does not guarantee the accuracy, integrity, or quality of generated content and that users must independently evaluate everything before acting on it. Verify citations before relying on any answer.
It is a paid-only service with a free 7-day trial for new users. The company does not publish an anonymously accessible price list. User reports on Google Play mention roughly $21.67 per month and a charge of $24.99, which indicate the general band but are not official rates — confirm current pricing in-app. The company states it honors all refunds within 30 days.
The vendor describes its base as official medical guidelines, published research, FDA drug labels, and real case reports, plus internally maintained guideline articles that it says are written by a multidisciplinary editorial team rather than AI-generated. Answers carry references so claims can be traced. Always check the date and content of a cited source — user feedback has flagged dated citations appearing in answers.
The company lists iPhone and iPad, Apple Vision, Android, and web browser, with one account working across devices. The iOS app requires iOS 15.1 or later and registers English as its only interface language. Content covers 24 specialties including cardiology, infectious disease, oncology, emergency medicine, pediatrics, obstetrics and gynecology, radiology, anesthesiology, and pathology.
Nothing in the company's public documentation claims regulatory clearance as a medical device or as clinical decision support software. The terms describe it as a text generation service intended to assist with general medical and scientific inquiry. Institutions with procurement requirements around regulated clinical software should confirm status directly with the vendor before deployment.
With restrictions. Access is granted for personal, non-commercial use only. If you republish generated content you must clearly cite the service along with the relevant context, and misrepresenting the source or nature of the content is prohibited. Automated collection and using the service as input to other services, websites, or databases are barred.
